| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure +1 more
Section 1. Registered Office. The registered office of Olema Oncology, Inc. (the “Corporation”) in the State of Delaware shall as set forth in the certificate of incorporation of the Corporation, as the same may be amended or restated fr... |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 |
| 16 Oct 2026 | SCHEDULE 13D/A |
| 15 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 12, 2026, Dr. Gorjan Hrustanovic notified Olema Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”), effective October 14, 2026. Dr. Hrustanovic also resigned fro... |
| 02 Sep 2026 |
Form 4: O'Byrne Jason, CHIEF FINANCIAL OFFICER
Granted 650,000 Stock Option (Right to Buy) |
| 13 Aug 2026 |
Form 3: O'Byrne Jason, CHIEF FINANCIAL OFFICER
No securities owned |
| 13 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Olema Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment as its Chief Financial Officer, pursuant to the terms of this offer letter agreement (the “Agreement”). |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 29 Jul 2026 | SCHEDULE 13G/A |
| 27 Jul 2026 |
Form 4: Harmon Cyrus, Director
Sold 12,500 shares ($145K) · Sold 12,500 shares ($146K) |
| 24 Jul 2026 | 144 |
| 23 Jul 2026 | 144 |
| 23 Jun 2026 |
Form 4: Bvf Partners L P/IL, Director and 9 others
Granted 29,500 Stock Option (Right to buy) |
| 23 Jun 2026 |
Form 4: Harmon Cyrus, Director
Granted 29,500 Stock Option (Right to Buy) |
| 23 Jun 2026 |
Form 4: Butitta Cynthia M, Director
Granted 29,500 Stock Option (right to buy) |
| 23 Jun 2026 |
Form 4: Garland J. Scott, Director
Granted 29,500 Stock Option (right to buy) |
Loading...